Brokers Offer Predictions for AstraZeneca FY2027 Earnings

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Investment analysts at Leerink Partnrs increased their FY2027 EPS estimates for shares of AstraZeneca in a report released on Monday, July 14th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of $5.83 per share for the year, up from their prior estimate of $5.81. The consensus estimate for AstraZeneca's current full-year earnings is $4.51 per share.

Several other equities research analysts have also recently weighed in on the company. BNP Paribas started coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of "Moderate Buy" and an average target price of $89.00.

AstraZeneca Price Performance

NASDAQ AZN opened at $70.32 on Wednesday. The company has a market cap of $218.08 billion, a PE ratio of 28.24, a price-to-earnings-growth ratio of 1.32 and a beta of 0.37. AstraZeneca has a 52 week low of $61.24 and a 52 week high of $87.68. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. The firm's 50-day simple moving average is $70.71 and its two-hundred day simple moving average is $70.88.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.06 EPS.

Institutional Investors Weigh In On AstraZeneca

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Dynamic Advisor Solutions LLC boosted its stake in AstraZeneca by 58.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company's stock worth $960,000 after buying an additional 4,811 shares in the last quarter. Geode Capital Management LLC boosted its stake in AstraZeneca by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock worth $32,683,000 after buying an additional 5,384 shares in the last quarter. Brandywine Global Investment Management LLC purchased a new stake in AstraZeneca in the fourth quarter worth approximately $28,071,000. Farther Finance Advisors LLC boosted its stake in AstraZeneca by 13.1% in the first quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company's stock worth $442,000 after buying an additional 706 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in AstraZeneca by 1.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 311,600 shares of the company's stock worth $22,903,000 after buying an additional 5,557 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.